Evaluation of the effects of citalopram and doxepin in patients with chronic obstructive pulmonary disease

Evaluation of the effects of Escitalopram and Doxepin on improving anxiety and depression and quality of life in patients with chronic obstructive pulmonary disease (COPD)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161023030452N2

Enrollment

Registered

2021-06-04

Start date

2021-05-10

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Depression. Condition 2: Anxiety. Condition 3: Chronic obstructive pulmonary disease. Other depressive episodes Anxiety disorder due to known physiological condition Other chronic obstructive pulmonary disease

Interventions

Intervention 1: Intervention group: Doxepin 25 mg of the tricyclic antidepressant drug is given as a capsule from Sobhan Pharmaceutical Company once a day for two months to 24 patients with chronic ob

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 40 years Having any class of COPD with any severity Having symptoms of depression and anxiety Patients with stable COPD so that their disease status does not change from day to day and are under constant treatment and there is no change in the type of treatment

Exclusion criteria

Exclusion criteria: Those whose illness has worsened recently (one week from the start of the study) or while studying Patients with severe dementia, severe cognitive impairment, end-stage cancer, and mental illness, including schizophrenia, suicidal ideation, and more Patients who have recently (two weeks after the start of the study) taken monoamine oxidase inhibitors or those who are taking these medications Patients whose ECG shows long QT intervals Pregnant or lactating women Patients with severe liver, kidney, cardiovascular and motor diseases Patients with uncontrollable epilepsy Patients with a history of intolerance to antidepressants

Design outcomes

Primary

Measure	Time frame
Depression score in the questionnaire. Timepoint: Depression at the beginning of the study (before the intervention) 14 days 30 days and 60 days after the intervention. Method of measurement: DASS 21 Questionnaire.;Anxiety score in the questionnaire. Timepoint: Anxiety at the beginning of the study (before the intervention) 14 days 30 days and 60 days after the intervention. Method of measurement: DASS 21 Questionnaire.;Stress score in the questionnaire. Timepoint: Stress at the beginning of the study (before the intervention) 14 days 30 days and 60 days after the intervention. Method of measurement: DASS 21 Questionnaire.;Physical health score in the questionnaire. Timepoint: Physical health score at the beginning of the study (before the intervention) 14 days 30 days and 60 days after the intervention. Method of measurement: WHOQOL-BREF questionnaire.;Mental health score in the questionnaire. Timepoint: Mental health score at the beginning of the study (before the intervention) 14 days 30 days and 60 days after the intervention. Method of measurement: WHOQOL-BREF questionnaire.;Social relations score in the questionnaire. Timepoint: Social relations score at the beginning of the study (before the intervention) 14 days 30 days and 60 days after the intervention. Method of measurement: WHOQOL-BREF questionnaire.;Environmental health score. Timepoint: Environmental health score at the beginning of the study (before the intervention) 14 days 30 days and 60 days after the intervention. Method of measurement: WHOQOL-BREF questionnaire.;General health score (quality of life). Timepoint: General health score (quality of life) at the beginning of the study (before the intervention) 14 days 30 days and 60 days after the intervention. Method of measurement: WHOQOL-BREF questionnaire.	—

Measure

Time frame

Depression score in the questionnaire. Timepoint: Depression at the beginning of the study (before the intervention) 14 days 30 days and 60 days after the intervention. Method of measurement: DASS 21 Questionnaire.;Anxiety score in the questionnaire. Timepoint: Anxiety at the beginning of the study (before the intervention) 14 days 30 days and 60 days after the intervention. Method of measurement: DASS 21 Questionnaire.;Stress score in the questionnaire. Timepoint: Stress at the beginning of the study (before the intervention) 14 days 30 days and 60 days after the intervention. Method of measurement: DASS 21 Questionnaire.;Physical health score in the questionnaire. Timepoint: Physical health score at the beginning of the study (before the intervention) 14 days 30 days and 60 days after the intervention. Method of measurement: WHOQOL-BREF questionnaire.;Mental health score in the questionnaire. Timepoint: Mental health score at the beginning of the study (before the intervention) 14 days 30 days and 60 days after the intervention. Method of measurement: WHOQOL-BREF questionnaire.;Social relations score in the questionnaire. Timepoint: Social relations score at the beginning of the study (before the intervention) 14 days 30 days and 60 days after the intervention. Method of measurement: WHOQOL-BREF questionnaire.;Environmental health score. Timepoint: Environmental health score at the beginning of the study (before the intervention) 14 days 30 days and 60 days after the intervention. Method of measurement: WHOQOL-BREF questionnaire.;General health score (quality of life). Timepoint: General health score (quality of life) at the beginning of the study (before the intervention) 14 days 30 days and 60 days after the intervention. Method of measurement: WHOQOL-BREF questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.S.A. Ghoreishi

Zanjan University of Medical Sciences

sabgho@zums.ac.ir+98 33 3354 4001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026